Infectious Agents and Cancer最新文献

Progression from infection with human papillomavirus (HPV) to cervical cancer in some women is thought to involve a permissive host environment, one in which immune response is mobilized in an inappropriate manner. Interleukin-2 (IL-2) is one of the most studied cytokines driving T-cell proliferation and survival. Soluble Interleukin-2 receptor (sIL2R) was found to play an immunoregulatory role and is detected in the serum of healthy individuals but increases in association with certain types of neoplasms. The aim of the current study was to assess the serum level of sIL2R in HPV infected female patients with genital warts compared to healthy control women and to correlate the results with cervical cytology (pap smear) results to determine the utility of measuring the serum sIL2R levels in screening of precancerous changes in cervix. The study was conducted on 90 Egyptian female patients with genital warts and 90 apparently healthy controls. Cervical brush samples were taken for both conventional Pap cytology and detection of HPV-DNA. Serum levels of sIL2R were measured by enzyme-linked immunosorbent assay (ELISA). Patients were divided into two groups according to the result of Pap smear: group 1 with Low-grade squamous intraepithelial lesion (LSIL) having flat condyloma on cervix and group 2 with normal pap smear having condyloma accuminata lesions. Serum sIL2R levels of HPV infected patients showed a statistically significant higher median when compared to controls (p value < 0.0001). Also, group 1 showed a statistically significant higher median compared to group 2 regarding sIL2R levels (p value < 0.0001). sIL2R was found to be perfect and reliable in differentiation between group 1 and group 2. Also, it may be useful to use serum sIL2R level for screening of HPV infections and cervical cancer.

The complex interplay between parasites and cancer is yielding promising advances in the field of cancer therapeutics. This study explored the in vitro anti-cancer potential of parasite immunomodulators (antigens and antibodies) of Schistosoma mansoni, Trichinella spiralis, and Toxoplasma gondii on human HT-29 colorectal and HepG2 hepatocellular carcinoma cells using the MTT assay. Results revealed that those parasites' immunomodulators exhibited antineoplastic activity and demonstrated a statistically significant inhibition of both cancer cell lines' proliferation (P ˂0.05). Notably, Trichinella spiralis antigens and antibodies and anti-Toxoplasma gondii antibodies demonstrated the most statistically significant inhibitory effects on HT-29 colorectal cancer cells (36.65%, 49.9% and 50.43% respectively). For HepG2 hepatocellular carcinoma cells, Trichinella spiralis antigens and antibodies, as well as Toxoplasma gondii antigen, displayed the most statistically significant inhibitory effects (38.27%, 48.25% and 34.68% respectively). Interestingly, parasitic antibodies are particularly noteworthy, exhibiting the most significant inhibitory effects on both cancer cell lines. To the best of our knowledge, this is the first study to demonstrate the antineoplastic activity of parasites' antibodies against human colorectal cancer and hepatocellular carcinoma. These findings could enlighten the path for promising cancer therapeutic candidates. Future research should explore the antineoplastic potential of a broader range of parasites' immunomodulators and identify their mechanisms of action. This could represent a qualitative shift towards the development of innovative cancer therapeutic antibodies and cancer vaccine candidates of parasitic origin for cancer-targeted immunotherapy.

Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma with its occurrence and progression closely associated with Epstein-Barr virus (EBV) status. However, the molecular differences between EBV-positive and EBV-negative BL have not been comprehensively evaluated. Through targeted sequencing of a 475-gene panel in 27 BL cases, and RNA-seq and LncRNA-seq analyses of 25 cases, we found that EBV-negative tumors displayed a higher frequency of chromosomal amplifications, particularly at 7p12.2, 6q25.3 and 7q22.1. Two novel variants of KMT2D were identified in adult patients in the EBV-negative group. Furthermore, EBV-positive BL exhibited enriched FOXO1 mutations, in contrast to CCND3 hotspot variants in EBV-negative cases. Transcriptome profiling revealed 1,612 differentially expressed genes (DEGs), predominantly involved in the PI3K-AKT, Hippo, WNT, and mTOR pathways. LncRNA profiling identified three EBV-associated lncRNAs ((MSTRG.103766.1, MSTRG.33752.11, ENSTO0000400385.2) with potential prognostic relevance in BL. Immune deconvolution (CIBERSORT/xCELL) demonstrated elevated M1 macrophages infiltration in EBV-positive BL, which correlated with improved 24-month overall survival (68% vs. 41%, p = 0.02). SULT1C2P1 and KCNK5 emerged as M1-associated prognostic biomarkers. Our findings establish EBV as a key modulator of BL genomic instability and immune remodeling, leading us to hypothesize that EBV status defines distinct BL subtypes with unique therapeutic vulnerabilities, thereby enabling the future development of EBV-stratified precision therapies.

Background: Bladder cancer remains a global health challenge with marked demographic and regional disparities. Understanding long-term trends, risk factors, and projections is essential for effective prevention.

Methods: Data on bladder cancer were extracted from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. We focused on the effects of age, sex, risk factors, and the socio-demographic index (SDI) on the burden of bladder cancer and calculated the average annual percent change (AAPC) via joinpoint regression. Mendelian randomization (MR) to assess causal risk factors, and Bayesian age-period-cohort (BAPC) models to forecast future burden.

Results: From 1990 to 2021, the global age-standardized incidence rate slightly declined (AAPC = - 0.269), prevalence increased (AAPC = 0.145), and both mortality (AAPC = - 0.840) and DALYs (AAPC = - 1.022) decreased significantly. The burden was significantly higher among males and older adults and showed substantial variation across SDI regions. Smoking and high fasting plasma glucose were strongly associated with bladder cancer DALYs, accounting for 27.8% and 7.4%, respectively. MR studies have confirmed that smoking and testosterone levels can increase the risk of bladder cancer. The prediction results indicate that the global age-standardized incidence rate will moderately decrease from 2022 to 2050.

Conclusion: Despite a gradual decline in mortality and incidence, bladder cancer continues to impose a substantial health burden, particularly among males and in high-SDI regions. Smoking and high fasting glucose are key modifiable risk factors. Sustained prevention and resource allocation are essential to mitigate the rising absolute burden in aging populations.